

The Effects of Press-Fit Technique Combined with Tranexamic Acid on Duration of Surgery and Intraoperative Blood Loss in Primary Total Hip Arthroplasty

Review began 03/16/2022
Review ended 04/01/2022
Published 04/05/2022

© Copyright 2022
Çataltepe et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Aziz Çataltepe¹, Kadir Öznam¹

1. Department of Orthopedic Surgery and Traumatology, Medipol University, Istanbul, TUR

Corresponding author: Aziz Çataltepe, aziz.cataltepe@medipol.edu.tr

Abstract

Background: Prolonged operative time and blood loss may affect the success rate in total hip arthroplasty (THA). The aim of the current study was to evaluate the effects of the press-fit (PF) technique without screws combined with tranexamic acid (TXA) on operative time and intraoperative blood loss in THA.

Methods: We retrospectively evaluated 114 hips treated with THA between March 2017 and January 2021 in this study. The patients were divided into three groups, including PF-TXA group, only PF group, and screw group. PF-TXA group received intravenous (IV) 1 g TXA 15 minutes before surgical incision, followed by a peri-articular 1 g/50 ml TXA. Only the PF group and screw group did not receive TXA. The primary outcome measures were operative time and intraoperative blood loss. Secondary outcomes included postoperative blood loss, hemoglobin and hematocrit levels, allogeneic blood transfusions, length of hospital stay, the Harris Hip Score (HHS), and thromboembolic complications.

Results: Operative time was lower in the PF-TXA group than that in the only PF and the screw group ($p=0.0001$). Intraoperative blood loss was significantly different in the PF-TXA group compared with the only PF and the screw group (423 ml, 516 ml, and 534 ml; respectively). The patients who received the PF technique combined with TXA had significantly less hospital stay length than the only PF group and the screw group ($p=0.021$).

Conclusion: The findings obtained in this study suggest that although only the PF technique can provide a shorter operative time compared to using screws, less blood loss may not be obtained using this technique in THA. PF technique combined with TXA significantly decreased operation time and intraoperative blood loss as well as the length of hospital stay following primary THA.

Categories: Orthopedics

Keywords: intraoperative blood loss, operative time, tranexamic acid, press-fit technique, total hip arthroplasty

Introduction

The initial stability of cementless implants is one of the main concerns for primary total hip arthroplasty (THA) with an uncemented technique [1]. The initial stability of the cementless acetabular component can be achieved with the press-fit (PF) technique without screws [2,3]. PF technique has some advantages, such as better surface contact at the bone-implant interface, decreased vascular or nerve damage, and shorter operative time in comparison with a screw technique [4,5]. PF technique without screws may shorten the duration of surgery, which can contribute to less bleeding in THA [5,6]. Shorter operative time decreases the risk of adverse events during THA, such as anemia, associated with blood loss, surgical site infection, extended hospital length of stay, and hospital readmission [7,8]. In addition, administering tranexamic acid (TXA) potentially can help the surgeon to perform the surgery faster [9].

A prolonged operation time in THA may lead to bleeding from bony and soft-tissue surfaces [8]. Significant intraoperative and postoperative blood loss may occur owing to hyper-fibrinolysis induced by surgical trauma after THA with screw or without screw [6,10]. Excessive blood loss may lead to complications and diminish the success of the surgery [11,12]. Substantial blood loss is associated with allogeneic blood transfusion, which has potential adverse effects on the body of patients, including the transmission of infectious diseases, immunologic reaction, transfusion-related acute lung injury, mistransfusion, and febrile reactions [12,13]. To reduce blood loss intraoperatively and postoperatively, many methods such as autologous blood transfusion, controlled hypotensive regional anesthesia, intraoperative blood salvage, shorter operative time, and TXA have been developed [9,14]. In the field of orthopedic surgery, TXA has been widely applied to total knee arthroplasty (TKA) and THA to reduce total blood loss and blood transfusion [15-17].

How to cite this article

Çataltepe A, Öznam K (April 05, 2022) The Effects of Press-Fit Technique Combined with Tranexamic Acid on Duration of Surgery and Intraoperative Blood Loss in Primary Total Hip Arthroplasty. *Cureus* 14(4): e23833. DOI 10.7759/cureus.23833

Operation time has been found to provide insufficient information regarding PF technique in THA. Furthermore, although TXA may decrease total blood loss and transfusion rates after THA, intraoperative blood loss remains controversial in the literature. Hence, we determined to combine the PF technique with IV and peri-articular TXA to minimize the operation time and blood loss. The primary purpose of this study was to evaluate the effects of the PF technique combined with TXA on operative time and intraoperative blood loss in THA.

Materials And Methods

After obtaining ethical approval from the local ethics committee of Medipol University (E-10840098-772.02-2915), a cohort of 113 consecutive patients who were performed on between March 2017 and January 2021 with unilateral THA for end-stage osteoarthritis were retrospectively assessed in the present study. Two patients diagnosed with rheumatoid arthritis and five patients diagnosed with Crowe type III or IV developmental dysplasia were excluded from this study. Two patients were lost to follow-up. Three patients died of unrelated causes to the surgery. Thus, 114 hips in 101 patients who met inclusion criteria were assessed. The patients over the age of eighteen years were divided into three groups. A total of 41 hips in the PF-TXA group received TXA, while a total of 37 hips in the only PF and a total of 36 hips in the screw group did not receive TXA. All patients stopped the anticoagulant and non-steroidal anti-inflammatory agents (NSAID) seven days before the surgery. Written informed consent was obtained from all patients who participated in this study.

The decision on anesthetic techniques, such as general or spinal with epidural anesthesia, was to rely on the anesthesiologists who did not participate in this study. All operations were performed with the same operative technique using a posterolateral approach. All hips were treated with the same cementless prosthesis (Trilogy cup, Versys Fiber Metal Taper stem; Zimmer, Warsaw, Indiana, USA). At the beginning of the surgery, the PF-TXA group received an IV loading dose of 1 g of TXA (Transamine, 250 mg/5 ml; Pharmacia, Teva, Turkey) in 100 ml of normal saline 15 minutes before surgical incision, followed by a peri-articular of 1 g TXA with 50 ml saline solution injected into the capsule and around the peri-articular soft tissue immediately after performing hip prosthesis and capsular closure and before skin closure. In all hips, we asked the anesthesiologist to reduce the blood pressure in a safe zone during the surgery as a strategy to minimize intraoperative blood loss until the wound closed. We calculated intraoperative blood loss by weighing sponges and suction drainage. In each group, the sole drain was placed into the hip joint and removed when the 24-hour volume of drainage was less than 50 ml after the surgery. After removing the drain, all of the patients began full weight-bearing walking using a walker postoperative day 1.

All of the patients were administered a standard course of an antithrombotic agent, which was low molecular-weight heparin (LMWH) (enoxaparin sodium, 40 mg) at eight hours postoperatively and continued three weeks after the surgery. Prophylactic antibiotic (cefazolin sodium, 1000 mg) was administered to all patients 30 minutes before the surgery and continued postoperatively over 24 hours.

Criteria of allogenic blood transfusion were a postoperative hemoglobin level of ≤ 8 g/dl, or a postoperative hemoglobin level between 8 and 10 g/dL with the clinical signs of hemodynamic instability, including lightheadedness, presyncope, and palpitation or shortness of breath not owing to other causes. Pre-donation of autologous blood was not administered for any patients. We calculated total blood volume (TBV) using the Nadler method [18]. Estimated blood loss (EBL) was monitored using Gross's formula, which considers the initial hematocrit before surgery, the minimum postoperative hematocrit level, and the average of the initial and minimum hematocrit levels [19]. Measured blood loss (MBL) was calculated as the sum of the intraoperative blood loss plus the total drain output. Operative time, intraoperative blood loss, EBL, length of hospital stay, thromboembolic complications, and demographic variables were assessed. The Harris Hip Score (HHS) was determined before operation and at the most recent follow-up.

Number Cruncher Statistical System (NCSS) 2007 Statistical Software (Utah, USA) program was used for statistical analysis. We expressed nominal data as frequencies or percentages and quantitative data as mean \pm SD. The Shapiro-Wilk test was performed for testing the normality of study data. The one-way analysis of variance (ANOVA) test and the repeated one-way ANOVA test were used to detect differences between patients from each group for normal distributions. Groups were compared using the independent t-test for normally distributed continuous variables. The paired t-test was used to analyze preoperative and postoperative assessments of the HHS. The Chi-square test was used to analyze qualitative comparative parameters. We compared subgroups using Tukey's multiple comparisons test. A p-value of ≤ 0.05 was considered statistically significant.

Results

This retrospective comparative study involved 114 hips undergoing unilateral THA from 2017 to 2020 with a mean age of 58.2 years. All subject demographics, including age, gender, body mass index (BMI), American Society of Anesthesiologists (ASA) status, TBV, and preoperative hemoglobin levels, were similar among the three groups ($p > 0.05$) (Table 1).

Variable		PF-TXA Group n=41		Only PF Group n=37		Screw Group n=36		p-value
Mean age (year)		55.17±15.31		58.46±12.87		57.03±12.4		0.568*
Gender	Male	8	19.51%	12	32.43%	8	22.22%	0.385+
	Female	33	80.49%	25	67.57%	28	77.78%	
BMI		28.69±5.06		26.59±3.13		28.47±4.63		0.077*
ASA	1	22	53.66%	18	48.65%	17	47.22%	0.714+
	2	16	39.02%	14	37.84%	17	47.22%	
	3	3	7.32%	5	13.51%	2	5.56%	
Side (right/left)	Right	19	46.34%	22	59.46%	12	33.33%	0.082+
	Left	22	53.66%	15	40.54%	24	66.67%	
Diagnosis	Primary OA	28	68.29%	28	75.68%	25	69.44%	0.751+
	AVN	5	12.20%	2	5.41%	2	5.56%	
	Crowe I DDH	5	12.20%	3	8.11%	3	8.33%	
	Crowe II DDH	3	7.32%	4	10.81%	5	13.89%	
	Posttraumatic	0	0.00%	0	0.00%	1	2.78%	
Type of anesthesia	General	6	14.63%	9	24.32%	9	25.00%	0.451+
	Regional	35	85.37%	28	75.68%	27	75.00%	
BP		10.22±0.86		10.3±0.95		9.89±0.54		0.073*
HR		63.15±6.3		62.97±5.91		64.56±6.03		0.476*
Hospital stay (day)		3.15±0.36		3.30±0.46		3.44±0.56		0.021*
Total blood volume (ml)		4309.67±661.47		4346.43±586.76		4345.09±688.26		0.960*
Operation time (min)		73.49±8.42		81.03±7.46		92.33±10.07		0.0001*
HHS								
Preoperative		38.24±4.12		38.59±4.15		36.56±5.35		0.127*
Postoperative		88.27±5.9		90.27±5.5		88.72±5.93		0.288*
p-value†		0.0001		0.0001		0.0001		

TABLE 1: Demographic characteristics of the patients.

Values presented as mean (standard deviation) and p calculated by using *the one-way analysis of variance (ANOVA) test, †the paired t-test, and ‡the Chi-square test.

BMI: body mass index; ASA: American Society of Anesthesiologists; OA: osteoarthritis; AVN: avascular necrosis; DDH: developmental dysplasia of the hip; HR: heart rate; BP: blood pressure; HHS: Harris hip score.

The duration of the operation was lower in the PF-TXA group than the only PF group and the screw group (73.49±8.42 min, 81.03±7.46, and 92.33±10.07, respectively; p=0.0001) (Table 1). There was significantly less intraoperative blood loss found in the PF-TXA group compared to the only PF group and the screw group (257.93±67.25 ml, 395.14±79.34 ml, and 412.50±122.79 ml, respectively; p=0.0001). Furthermore, EBL was 990.01±166.97 ml in the PF-TXA group, significantly lower than 1362.13±312 ml in the only PF group and 1477.99±314.72 ml in the screw group (p=0.0001). Hemoglobin and hematocrit reduction were also significantly lower in the PF-TXA group (p=0.0001) (Table 2).

Variable	PF-TXA Group n=41	Only PF Group n=37	Screw Group n=36	p-value*
Intraoperative blood loss (ml)	257.93±67.25	395.14±79.34	412.50±122.79	0.0001
Drainage blood loss (ml)	312.32±101.61	459.41±132.61	510.28±138.74	0.0001
Estimated blood loss (ml)	990.01±166.97	1362.13±312	1477.99±314.72	0.0001
Hemoglobin (g/dl)				
Preoperative	13.00±1.19	13.14±1.18	13.01±1.17	0.849
Postoperative 1st day	11.37±1.16	11.31±1.23	11.20±1.06	0.810
Postoperative 2nd day	10.78±1.21	10.40±1.16	10.14±1.16	0.059
Postoperative 3rd day	10.32±1.09	9.62±1.14	9.16±1.11	0.0001
p‡	0.0001	0.0001	0.0001	
Hemoglobin reduction (g/dl)	2.1±0.43	3.51±0.54	3.82±0.69	0.0001
Hematocrit (%)				
Preoperative	39.27±3.57	39.65±3.31	39.10±3.38	0.777
Postoperative 1st day	34.43±3.33	34.23±3.47	33.81±3.11	0.714
Postoperative 2nd day	32.57±3.42	31.66±3.24	30.84±3.35	0.081
Postoperative 3rd day	31.17±3.18	29.07±3.18	27.82±3.13	0.0001
p-value‡	0.0001	0.0001	0.0001	
Hematocrit reduction (%)	8.19±1.23	10.66±1.45	11.4±1.89	0.0001

TABLE 2: Blood loss calculation, hemoglobin, hematocrit, and its reduction.

Values presented as mean (standard deviation) and p calculated by using * the one-way analysis of variance (ANOVA) test and ‡the repeated one-way ANOVA test.

Whereas the only PF group had a shorter operation time compared to the screw group (p=0.0001), any significant differences regarding intraoperative blood loss, postoperative drainage volume, and total blood loss between the screw and PF group were observed (Table 3).

Variable	Operation time (min)	Intraoperative blood loss (ml)	Drainage blood loss (ml)	Estimated blood loss (ml)
PF-TXA Group/Only PF Group	0.001	0.0001	0.0001	0.0001
PF-TXA Group/Screw Group	0.0001	0.0001	0.0001	0.0001
Only PF Group/Screw Group	0.0001	0.699	0.193	0.163

TABLE 3: Comparison of the three subgroups.

P calculated by using Tukey's multiple comparisons test.

Regarding the blood transfusion rate, six of 41 hips (14.63%) in the PF-TXA group received blood transfusions, whereas 13 of 36 hips (36.11%) in the PF group and 14 of 36 hips (38.89%) in the screw group received blood transfusions (Table 4).

Variable		N	Hospital stay (day)	p-value*
PF-TXA Group	Transfusion (-)	35	3.09±0.29	0.021
	Transfusion (+)	6	3.43±0.54	
Only PF Group	Transfusion (-)	24	3.04±0.21	0.0001
	Transfusion (+)	13	3.71±0.47	
Screw Group	Transfusion (-)	22	3.23±0.43	0.0001
	Transfusion (+)	14	3.79±0.58	

TABLE 4: The correlation between blood transfusion and the length of hospital stay.

Values presented as mean (standard deviation) and p calculated by using * the independent t-test.

Patients who received the PF technique combined with TXA had significantly less length of hospital stay compared to the only PF group and the screw group ($p=0.021$). There was no significant difference among the three groups concerning the mean HHS score, which improved in all groups. In the PF-TXA group, one patient encountered pulmonary embolism (PE) treated with LMWH. One patient in the only PF group and two patients in the screw group experienced superficial wound infection, which was successfully treated with antibiotics. There was no neurovascular damage in all groups.

Discussion

After evaluation of the findings, the main outcomes in the current study were a shortened operation time and reduced intraoperative blood loss in hips treated with PF and TXA. Operation time identified as a crucial independent factor may have an adverse effect on the clinical outcome of THA [20]. Småbrekke et al. suggested that the potential benefits of shorter operating times should be considered by orthopedic surgeons [21]. The duration of the surgical procedure can be modified to reduce complications after total joint arthroplasty [8]. Operation time which has been found insufficient information regarding PF technique for acetabular reconstruction is a changeable factor among orthopedic surgeons. PF technique without screws may shorten the duration of surgery, which can contribute to less bleeding [5,6]. Pepe et al. indicated that acetabular components with or without screws have consistent findings, but the use of screws increases the operation time significantly [6]. Similar outcomes were found in the current study in which only the PF group had a significantly shorter operative time compared to the screw group. Furthermore, Sandri et al. conducted a comparative retrospective study in which 40 patients received 1 g of IV-TXA before surgery, followed by 1 g of IV-TXA after surgery [9]. According to the findings obtained in this study, the mean operation time in the TXA group was significantly lower than in the control group. By contrast, Remérand et al. applied 15 mg/kg IV-TXA and found that although the operative time in the TXA group was shorter than the control group, there was no statistically significant difference between the two groups [22]. We applied the PF technique combined with TXA in the current study that showed that the mean operation time was significantly less compared with the only PF and the screw group. The operative time may be reduced using TXA and PF techniques owing to early hemostasis, better visibility of the operative field, and the advantage of not using screws which can save time. Moreover, prolonged operative time may be affected by a variety of factors such as an inexperienced surgeon, a generally slow-working surgeon, an inexperienced operating team, or a combination of these factors [21]. In the present study, the surgeon who had at least 18 years' experience in hip arthroplasty surgery performed THA.

There are insufficient statistical data about intraoperative blood loss in THA fixed with PF fixation without screws in the literature. We obtained only one study conducted by Pepe et al. who did not find any significant difference regarding intraoperative blood loss and postoperative drainage volume and the total blood loss between the screw and PF group [6]. The same conclusion was drawn by the current study in which there was no significant difference concerning intraoperative and total blood loss between only the PF group and the screw group. In addition, although TXA may reduce total blood loss and transfusion rates after THA, intraoperative blood loss remains controversial in the literature. Claeys et al. and Johansson et al. performed a randomized controlled double-blinded trial examining the effects of IV-TXA on THA [23,24]. They reported that TXA was demonstrated a non-significant reduction in intraoperative blood loss and operation time compared to the control group. On the other hand, Ekbäck et al. showed that TXA significantly reduced intraoperative blood loss in the TXA group compared with the control group [25]. According to the current study, significant differences regarding shorter operation time and less intraoperative blood loss can be reached by combining the PF technique and TXA. To our knowledge, this is the first report that shows the effects of PF combined with TXA on operation time and intraoperative blood loss.

A prolonged operation time in THA may lead to bleeding from bony and soft-tissue surfaces [8]. Bohl et al.

conducted a study in which there were 165,474 patients and found a strong relationship between operation time and anemia requiring blood transfusion [8]. The same conclusion was drawn by Salido et al. who showed that increased operative time had a higher risk of transfusion [26]. In this study, the patients who received blood transfusion had a longer operative time (96 min) than patients who did not receive a blood transfusion (87 min). König et al. applied topical TXA to reduce blood loss in 91 patients and compared it to 40 patients who did not receive TXA [27]. They showed that postoperative transfusions were reduced dramatically using TXA, dropping from 15% to 1% in THA. In the current study, we observed that the PF-TXA group had fewer blood transfusions than that in the only PF and the screw group.

The prolonged surgical duration may result in extended hospital length of stay [8,28]. Bohl et al. evaluated 165,474 knees and hips and found that an increase in operative time of 15 minutes was associated with an increase in the risk of anemia requiring transfusion by 9% and the risk of extended hospital length of stay by 9% [8]. Zeng et al. compared two groups (the TXA and the control group) and showed that intraoperative blood loss, total blood loss, and transfusion rates were significantly lower in the TXA group compared with the control group; however, length of stay after surgery did not show any significant difference [29]. In the present study, we found a statistically significant difference in the length of hospital stays in the PF-TXA group compared with the screw group, which had a mean longer operation time. The discrepancy in the length of hospital stay might be associated with patients who received blood transfusions, with a slightly slower postoperative recovery.

In the current study, the mean HHS was 88.27 ± 5.9 in the PF-TXA group, 90.27 ± 5.5 in the only PF group, and 88.72 ± 5.93 in the screw group at the end of the study. Similar to the literature findings, the current study did not reveal any significant differences between the three groups. TXA did not increase the risk of thromboembolic complications, such as deep venous thrombosis (DVT) and PE, regardless of the administration route [30]. However, in the current study, PE treated with LMWH occurred in one hip in the PF-TXA group. This hip was not administered any blood transfusion, but the patient has smoked two packages of cigarettes a day for 22 years. Moreover, when the open surgical site and the surgical instruments are exposed to longer operation time, bacteria from the operating room environment may pose severe problems for THA, including surgical site infection and wound dehiscence [8,28]. One patient in the only PF group and two patients in the screw group experienced superficial wound infection, successfully treated with antibiotics.

We are aware that our data have some limitations. The main limitation of this study is its retrospective design. The number of included hips is relatively less, and this could result in the potential underpowering of the current study. Ultrasound examination could be applied at the follow-up to find asymptomatic DVT. All hips are performed by the same surgical and the same anesthetic team, which could reduce the potential surgical variability and perioperative blood loss.

Conclusions

In conclusion, although only the PF technique can provide a shorter operative time compared to using screws, less blood loss may not be obtained using this technique in THA. The findings obtained in the present study suggested that the PF technique combined with TXA significantly decreased operation time and intraoperative blood loss as well as the length of hospital stay following primary THA.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Local Ethics Committee of Medipol University issued approval E-10840098-772.02-2915. **Animal subjects:** All authors have confirmed that this study did not involve animal subjects or tissue. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Acknowledgements

Special thanks to Renza Konyalioglu, who is a statistician.

References

1. Curtis MJ, Jinnah RH, Wilson VD, Hungerford DS: The initial stability of uncemented acetabular components. *J Bone Joint Surg Br.* 1992, 74:372-6. [10.1302/0501-620X.74B3.1587880](https://doi.org/10.1302/0501-620X.74B3.1587880)
2. Kwong LM, O'Connor DO, Sedlacek RC, Krushell RJ, Maloney WJ, Harris WH: A quantitative in vitro assessment of fit and screw fixation on the stability of a cementless hemispherical acetabular component. *J Arthroplasty.* 1994, 9:163-70. [10.1016/0883-5403\(94\)90065-5](https://doi.org/10.1016/0883-5403(94)90065-5)

3. Schmalzried TP, Hill GC, Wessinger SJ, Harris WH: The Harris-Galante porous acetabular component press-fit without screw fixation: five-year radiographic analysis of primary cases. *J Arthroplasty*. 1994, 9:235-42. [10.1016/0883-5403\(94\)90077-9](https://doi.org/10.1016/0883-5403(94)90077-9)
4. Keating EM, Ritter MA, Faris PM: Structures at risk from medially placed acetabular screws. *J Bone Joint Surg*. 1990, 72:509-11.
5. Iorio R, Puskas B, Healy WL, Tilzey JF, Specht LM, Thompson MS: Cementless acetabular fixation with and without screws: analysis of stability and migration. *J Arthroplasty*. 2010, 25:309-13. [10.1016/j.arth.2009.01.023](https://doi.org/10.1016/j.arth.2009.01.023)
6. Pepe M, Kocadal O, Erener T, Ceritoglu K, Aksahin E, Aktekin CN: Acetabular components with or without screws in total hip arthroplasty. *World J Orthop*. 2017, 8:705-9. [10.5312/wjo.v8.i9.705](https://doi.org/10.5312/wjo.v8.i9.705)
7. Duchman KR, Pugely AJ, Martin CT, Gao Y, Bedard NA, Callaghan JJ: Operative time affects short-term complications in total joint arthroplasty. *J Arthroplasty*. 2017, 32:1285-91. [10.1016/j.arth.2016.12.003](https://doi.org/10.1016/j.arth.2016.12.003)
8. Bohl DD, Ondeck NT, Darrith B, Hannon CP, Fillingham YA, Della Valle CJ: Impact of operative time on adverse events following primary total joint arthroplasty. *J Arthroplasty*. 2018, 33:2256-62.e4. [10.1016/j.arth.2018.02.037](https://doi.org/10.1016/j.arth.2018.02.037)
9. Sandri A, Mimor BF, Ditta A, et al.: Perioperative intravenous tranexamic acid reduces blood transfusion in primary cementless total hip arthroplasty. *Acta Biomed*. 2019, 90:81-6. [10.23750/abm.v90i1-S.8085](https://doi.org/10.23750/abm.v90i1-S.8085)
10. Murphy WG, Davies MJ, Eduardo A: The haemostatic response to surgery and trauma. *Br J Anaesth*. 1995, 70:205-13. [10.1093/bja/70.2.205](https://doi.org/10.1093/bja/70.2.205)
11. Sizer SC, Cherian JJ, Elmallah RD, Pierce TP, Beaver WB, Mont MA: Predicting blood loss in total knee and hip arthroplasty. *Orthop Clin North Am*. 2015, 46:445-59. [10.1016/j.ocl.2015.06.002](https://doi.org/10.1016/j.ocl.2015.06.002)
12. Frisch NB, Wessell NM, Charters MA, Yu S, Jeffries JJ, Silverton CD: Predictors and complications of blood transfusion in total hip and knee arthroplasty. *J Arthroplasty*. 2014, 29:189-92. [10.1016/j.arth.2014.03.048](https://doi.org/10.1016/j.arth.2014.03.048)
13. Goodnough LT: Risks of blood transfusion. *Anesthesiol Clin North Am*. 2005, 23:241-52. [10.1016/j.atc.2004.07.004](https://doi.org/10.1016/j.atc.2004.07.004)
14. Sharrock NE, Mineo R, Urquhart B, Salvati EA: The effect of two levels of hypotension on intraoperative blood loss during total hip arthroplasty performed under lumbar epidural anesthesia. *Anesth Analg*. 1993, 76:580-4.
15. Poeran J, Rasul R, Suzuki S, et al.: Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety. *BMJ*. 2014, 349:g4829. [10.1136/bmj.g4829](https://doi.org/10.1136/bmj.g4829)
16. Whiting DR, Gillette BP, Duncan C, Smith H, Pagnano MW, Sierra RJ: Preliminary results suggest tranexamic acid is safe and effective in arthroplasty patients with severe comorbidities. *Clin Orthop Relat Res*. 2014, 472:66-72. [10.1007/s11999-013-3134-0](https://doi.org/10.1007/s11999-013-3134-0)
17. Montroy J, Hutton B, Moodley P, et al.: The efficacy and safety of topical tranexamic acid: A systematic review and meta-analysis. *Transfus Med Rev*. 2018, 32:165-78. [10.1016/j.tmr.2018.02.003](https://doi.org/10.1016/j.tmr.2018.02.003)
18. Nadler SB, Hidalgo JH, Bloch T: Prediction of blood volume in normal human adults. *Surgery*. 1962, 51:224-32. [10.5555/uri:pii:0039606062901666](https://doi.org/10.5555/uri:pii:0039606062901666)
19. Gross JB: Estimating allowable blood loss: corrected for dilution. *Anesthesiology*. 1983, 58:277-80. [10.1097/0000542-198303000-00016](https://doi.org/10.1097/0000542-198303000-00016)
20. Bredow J, Boese CK, Flörkemeier T, et al.: Factors affecting operative time in primary total hip arthroplasty: a retrospective single hospital cohort study of 7674 cases. *Technol Health Care*. 2018, 26:857-66. [10.3233/THC-171015](https://doi.org/10.3233/THC-171015)
21. Småbrekke A, Espehaug B, Havelin LI, Furnes O: Operating time and survival of primary total hip replacements: an analysis of 31,745 primary cemented and uncemented total hip replacements from local hospitals reported to the Norwegian Arthroplasty Register 1987-2001. *Acta Orthop Scand*. 2004, 75:524-32. [10.1080/00016470410001376](https://doi.org/10.1080/00016470410001376)
22. Remérand F, Cotten M, N'Guessan YF, et al.: Tranexamic acid decreases risk of haematomas but not pain after hip arthroplasty. *Orthop Traumatol Surg Res*. 2013, 99:667-73. [10.1016/j.otsr.2013.03.029](https://doi.org/10.1016/j.otsr.2013.03.029)
23. Claeys MA, Vermeersch N, Haentjens P: Reduction of blood loss with tranexamic acid in primary total hip replacement surgery. *Acta Chir Belg*. 2007, 107:397-401. [10.1080/00015458.2007.11680081](https://doi.org/10.1080/00015458.2007.11680081)
24. Johansson T, Pettersson LG, Lisander B: Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients. *Acta Orthop*. 2005, 76:314-9.
25. Ekbäck G, Axelsson K, Rytberg L, et al.: Tranexamic acid reduces blood loss in total hip replacement surgery. *Anesth Analg*. 2000, 91:1124-30. [10.1097/0000539-200011000-00014](https://doi.org/10.1097/0000539-200011000-00014)
26. Salido JA, Marín LA, Gómez LA, Zorrilla P, Martínez C: Preoperative hemoglobin levels and the need for transfusion after prosthetic hip and knee surgery: analysis of predictive factors. *J Bone Joint Surg Am*. 2002, 84:216-20. [10.2106/00004623-200202000-00008](https://doi.org/10.2106/00004623-200202000-00008)
27. König G, Hamlin BR, Waters JH: Topical tranexamic acid reduces blood loss and transfusion rates in total hip and total knee arthroplasty. *J Arthroplasty*. 2013, 28:1473-6. [10.1016/j.arth.2013.06.011](https://doi.org/10.1016/j.arth.2013.06.011)
28. Orland MD, Lee RY, Naami EE, Patetta MJ, Hussain AK, Gonzalez MH: Surgical duration implicated in major postoperative complications in total hip and total knee arthroplasty: a retrospective cohort study. *J Am Acad Orthop Surg Glob Res Rev*. 2020, 4:e20.00043. [10.5435/JAOSGlobal-D-20-00043](https://doi.org/10.5435/JAOSGlobal-D-20-00043)
29. Zeng Y, Si HB, Shen B, Yang J, Zhou ZK, Kang PD, Pei FX: Intravenous combined with topical administration of tranexamic acid in primary total hip arthroplasty: a randomized controlled trial. *Orthop Surg*. 2017, 9:174-9. [10.1111/os.12287](https://doi.org/10.1111/os.12287)
30. Reale D, Andriolo L, Gursoy S, Bozkurt M, Filardo G, Zaffagnini S: Complications of tranexamic acid in orthopedic lower limb surgery: a meta-analysis of randomized controlled trials. *Biomed Res Int*. 2021, 2021:1-14. [10.1155/2021/6961540](https://doi.org/10.1155/2021/6961540)